2026-02-24
Grip Strength as a Longevity Biomarker: Evidence and Interventions
Grip strength is one of the most powerful and accessible biomarkers of biological aging, predicting cardiovascular events, hospitalization, and all-cause mortality more reliably than many clinical tests. This article covers the mechanisms, evidence, and interventions.
2026-02-20
Creatine Plus Protein in Older Adults: Strength and Frailty-Relevant Outcomes
In older adults, creatine and adequate protein show the most consistent benefit when paired with resistance training, with practical relevance for sarcopenia and fall-risk prevention.
2026-02-20
Osteopenia and Fragility: Protein, Vitamin D3, and K2 in a Training-First Plan
For osteopenia and fragility risk, mechanical loading and fall prevention remain primary. Vitamin D3, K2, whey protein, and creatine may provide selective additive support.
2026-02-18
Rapamycin in Older Adults: PEARL Trial Findings on Dose, Sex Differences, and Body Composition
The PEARL trial tested low-dose weekly rapamycin in healthy older adults. The primary endpoint — visceral fat reduction — was not met. Secondary analyses suggested lean tissue effects at higher doses in women, but these require confirmation in adequately powered trials.
2026-02-18
Dasatinib and Quercetin for Senolytic Therapy: Mayo Clinic Phase 2 Trial Findings
A Mayo Clinic Phase 2 trial tested dasatinib plus quercetin in 60 older women with low bone density, finding improved bone formation markers. Dasatinib is an FDA-approved cancer drug requiring physician supervision.